Clinical Trial Update: Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating stereotactic radiotherapy to ablate oligometastatic, hormone-sensitive prostate cancer. The study is active but not recruiting and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: UNICANCER | Conditions: Oligometastatic Hormone Sensitive Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING